A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial

Sung Yong Oh, Won Seog Kim, Jin Seok Kim, Yee Soo Chae, Gyeong Won Lee, Hyeon Seok Eom, Hun Mo Ryoo, Suee Lee, Seok Jin Kim, Dok Hyun Yoon, Jong Ho Won, Junshik Hong, Jinny Park, Sang Min Lee, Jung Yong Hong, Eunkyung Park, Hyo Jung Kim, Deok Hwan Yang, Hyo Jin Kim, Cheolwon Suh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Overall, more than 50% of marginal zone lymphoma (MZL) patients experience a relapse within 10 years. This phase II trial was conductedto assess the efficacy and safety of oxaliplatin-prednisone (Ox-P) chemotherapy for patients with relapsed or refractory MZL. Patients received oxaliplatin 130 mg/m2 on day 1 and prednisone 100 mg/day on days 1-5 of each cycle. A total of 38 patients were enrolled. The median age of the 34 (16 males, 18 females) evaluated patients was 53 (range = 27-74) years. There were seven complete responses (20.6%) and 15 partial responses (44.1%) (Overall response rate = 64.7%). No treatment-related deaths occurred. The median progression-free survival was 14.2 months (95% CI = 2.1-26.3 months); 3-year overall survival rate was 77.7%. Thus, salvage Ox-P chemotherapy for patients with relapsed or refractory MZL at the stated dosage and schedule showed moderate clinical activity and was considerable in very few selected patients (NCT01068392).

Original languageEnglish
Pages (from-to)1406-1412
Number of pages7
JournalLeukemia and Lymphoma
Volume57
Issue number6
DOIs
Publication statusPublished - 2016 Jun 2

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial'. Together they form a unique fingerprint.

  • Cite this

    Oh, S. Y., Kim, W. S., Kim, J. S., Chae, Y. S., Lee, G. W., Eom, H. S., Ryoo, H. M., Lee, S., Kim, S. J., Yoon, D. H., Won, J. H., Hong, J., Park, J., Lee, S. M., Hong, J. Y., Park, E., Kim, H. J., Yang, D. H., Kim, H. J., & Suh, C. (2016). A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial. Leukemia and Lymphoma, 57(6), 1406-1412. https://doi.org/10.3109/10428194.2015.1099650